Title |
Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab
|
---|---|
Published in |
Scientific Reports, August 2016
|
DOI | 10.1038/srep31726 |
Pubmed ID | |
Authors |
Chiara Nicolazzo, Cristina Raimondi, MariaLaura Mancini, Salvatore Caponnetto, Angela Gradilone, Orietta Gandini, Maria Mastromartino, Gabriella del Bene, Alessandra Prete, Flavia Longo, Enrico Cortesi, Paola Gazzaniga |
Abstract |
Controversial results on the predictive value of programmed death ligand 1 (PD-L1) status in lung tumor tissue for response to immune checkpoint inhibitors do not allow for any conclusive consideration. Liquid biopsy might allow real-time sampling of patients for PD-L1 through the course of the disease. Twenty-four stage IV NSCLC patients included in the Expanded Access Program with Nivolumab were enrolled. Circulating tumor cells (CTCs) were analyzed by CellSearch with anti-human B7-H1/PD-L1 PE-conjugated antibody. PD-L1 expressing CTCs were assessed at baseline, at 3 and 6 months after starting therapy, and correlated with outcome. At baseline and at 3 months of treatment, the presence of CTCs and the expression of PD-L1 on their surface were found associated to poor patients outcome. Nevertheless, the high frequency of PD-L1 expressing CTCs hampered to discriminate the role of PD-L1 in defining prognosis. Conversely although CTCs were found in all patients 6 months after treatment, at this time patients could be dichotomized into two groups based PD-L1 expression on CTCs. Patients with PD-L1 negative CTCs all obtained a clinical benefit, while patients with PD-L1 (+) CTCs all experienced progressive disease. This suggests that the persistence of PD-L1(+) CTCs might mirror a mechanism of therapy escape. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Singapore | 1 | 50% |
Unknown | 1 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 2 | 1% |
India | 1 | <1% |
Israel | 1 | <1% |
Japan | 1 | <1% |
Canada | 1 | <1% |
Unknown | 177 | 97% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 38 | 21% |
Researcher | 31 | 17% |
Student > Master | 16 | 9% |
Student > Bachelor | 13 | 7% |
Student > Doctoral Student | 11 | 6% |
Other | 23 | 13% |
Unknown | 51 | 28% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 37 | 20% |
Biochemistry, Genetics and Molecular Biology | 33 | 18% |
Agricultural and Biological Sciences | 19 | 10% |
Engineering | 11 | 6% |
Immunology and Microbiology | 5 | 3% |
Other | 22 | 12% |
Unknown | 56 | 31% |